Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies

被引:47
作者
Salum, Livia de B. [1 ]
Polikarpov, Igor [1 ]
Andricopulo, Adriano D. [1 ]
机构
[1] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Biotecnol Mol Estrutural, Lab Quim Med & Computac, BR-13560 Sao Carlos, Brazil
基金
巴西圣保罗研究基金会;
关键词
estrogen receptor; drug design; breast cancer; CoMFA; HQSAR;
D O I
10.1016/j.jmgm.2007.02.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The estrogen receptor (ER) is an important drug target for the development of novel therapeutic agents for the treatment of breast cancer. Progress towards the design of more potent and selective ER modulators requires the optimization of multiple ligand-receptor interactions. Comparative molecular field analyses (CoMFA) and hologram quantitative structure-activity relationships (HQSAR) were conducted on a large set of ER alpha modulators. Two training sets containing either 127 or 69 compounds were used to generate QSAR models for in vitro binding affinity and potency, respectively. Significant correlation coefficients (affinity models, CoMFA, r(2) = 0.93 and q(2) = 0.79; HQSAR, r(2) = 0.92 and q(2) = 0.71; potency models, CoMFA, r(2) = 0.94 and q(2) = 0.72; HQSAR, r(2) = 0.92 and q(2) = 0.74) were obtained, indicating the potential of the models for untested compounds. The generated models were validated using external test sets, and the predicted values were in good agreement with the experimental results. The final QSAR models as well as the information gathered from 3D contour maps should be useful for the design of novel ERa modulators having improved affinity and potency. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:434 / 442
页数:9
相关论文
共 52 条
[1]   Estrogen receptors as therapeutic targets in breast cancer [J].
Ariazi, Eric A. ;
Ariazi, Jennifer L. ;
Cordera, Fernando ;
Jordan, V. Craig .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (03) :181-202
[2]   Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies [J].
Avery, MA ;
Alvim-Gaston, M ;
Rodrigues, CR ;
Barreiro, EJ ;
Cohen, FE ;
Sabnis, YA ;
Woolfrey, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (02) :292-303
[3]   Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain [J].
Blizzard, TA ;
DiNinno, F ;
Chen, HY ;
Kim, S ;
Wu, JY ;
Chan, WD ;
Birzin, ET ;
Yang, YT ;
Pal, LY ;
Hayes, EC ;
DaSilva, CA ;
Rohrer, SP ;
Schaeffer, JM ;
Hammond, ML .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (17) :3912-3916
[4]   Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers [J].
Blizzard, TA ;
DiNinno, F ;
Morgan, JD ;
Chen, HY ;
Wu, JY ;
Kim, S ;
Chan, W ;
Birzin, ET ;
Yang, YT ;
Pai, LY ;
Fitzgerald, PMD ;
Sharma, N ;
Li, Y ;
Zhang, ZP ;
Hayes, EC ;
DaSilva, CA ;
Tang, W ;
Rohrer, SP ;
Schaeffer, JM ;
Hammond, ML .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (01) :107-113
[5]   Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains [J].
Blizzard, TA ;
DiNinno, F ;
Morgan, JD ;
Wu, JY ;
Chen, HY ;
Kim, S ;
Chan, WD ;
Birzin, ET ;
Yang, YT ;
Pai, LY ;
Zhang, ZP ;
Hayes, EC ;
DaSilva, CA ;
Tang, W ;
Rohrer, SP ;
Schaeffer, JM ;
Hammond, ML .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (15) :3865-3868
[6]  
BLIZZARD TA, 2004, BIOORG MED CHEM LETT, V14, P3664
[7]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[8]   Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors [J].
Castilho, MS ;
Postigo, MP ;
de Paula, CBV ;
Montanari, CA ;
Oliva, G ;
Andricopulo, AD .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (02) :516-527
[9]   Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs [J].
Chen, HY ;
Kirn, S ;
Wu, JY ;
Birzin, ET ;
Chan, W ;
Yang, YT ;
Dahllund, J ;
DiNinno, F ;
Rohrer, SP ;
Schaeffer, JM ;
Hammond, ML .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (10) :2551-2554
[10]   Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity [J].
Chen, HY ;
Dykstra, KD ;
Birzin, ET ;
Frisch, K ;
Chan, W ;
Yang, YT ;
Mosley, RT ;
DiNinno, F ;
Rohrer, SP ;
Schaeffer, JM ;
Hammond, ML .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (06) :1417-1421